Sandra Myerson, MBA, MS, BSN, RN, has been appointed to the newly created position of Senior Vice President and Chief Patient Experience Officer of the Mount Sinai Health System and of The Joseph F. Cullman Jr. Institute for Patient Care at The Mount Sinai Hospital. Ms. Myerson will collaborate with leadership to further establish a patient-centered culture across all inpatient and outpatient settings. (more…)
Elizabeth Peralta, a Laboratory Technician at The Mount Sinai Hospital, lost 55 pounds in five months and reversed her diagnosis of type 2 diabetes with help from The Diabetes Alliance at the Mount Sinai Health System. The Diabetes Alliance offers Mount Sinai staff and patients personalized diabetes education, nutrition, and counseling and support to achieve their health and wellness goals.
The quick turnaround for Ms. Peralta started in July, after a routine physical with her internist, Laurie Edelman, MD, revealed that her blood sugar level had significantly increased over the prior year, resulting in a diagnosis of uncontrolled type 2 diabetes. Dr. Edelman is an Associate Professor in the Division of General Internal Medicine at Icahn School of Medicine at Mount Sinai. (more…)
The Joint Commission, the leading accreditor of health care organizations in the United States, has designated Mount Sinai Beth Israel, Mount Sinai St. Luke’s, and Mount Sinai Roosevelt as “Top Performers on Key Quality Measures,” based on data from 2013.
The “Top Performer” program recognizes institutions for improving performance on evidence-based interventions that increase the likelihood of good medical outcomes for patients with certain conditions. As “Top Performers,” the hospitals will be included in The Joint Commission’s America’s Hospitals: Improving Quality and Safety, an online annual report found at http://bit.ly/1xMz5qM and also on The Joint Commission’s Quality Check® website.
“We have learned that the impossible is possible, and advances are being made that we could not have imagined just a few years ago,” said Dennis S. Charney, MD, Anne and Joel Ehrenkranz Dean, Icahn School of Medicine at Mount Sinai, and President for Academic Affairs, Mount Sinai Health System, at the conclusion of the school’s third annual SinaInnovations conference in November.
The conference, which took place on campus Tuesday and Wednesday, November 18 and 19, respectively, focused on breakthroughs in medicine and engineering that improve human health and was sponsored jointly with Mount Sinai’s academic affiliate Rensselaer Polytechnic Institute (RPI).
Researchers at the Icahn School of Medicine at Mount Sinai have received more than $31 million from the National Institutes of Health (NIH) to create three new centers that will study how drugs interact with human cells to increase their effectiveness and decrease side effects.
A new Drug Toxicity Signature Center will be run by Ravi Iyengar, PhD, Dorothy H. and Lewis Rosenstiel Professor, Department of Pharmacology and Systems Therapeutics, who has received a grant totaling $11.6 million from the NIH. By leveraging the U.S. Food and Drug Administration’s (FDA) Adverse Event Reporting System database, the center will develop cell signatures that can be used to predict the effects of certain drugs and drug combinations.
While competing in a 1,500-meter triathlon swim in the Hudson River in August, Chris LaPak, 52, experienced sudden cardiac arrest. A Herculean rescue effort ensued, with first responders moving him quickly from a surfboard to a jet ski to a boat and finally to a pier. Attempts at cardiopulmonary resuscitation (CPR) failed, leaving Mr. LaPak—the president of a pharmaceutical printing company—without a pulse for at least nine minutes before he was finally resuscitated with an automated-external defibrillator.